Latest Pharmaceutical Pricing News

Adheris Health has achieved cashflow break-even in Q4 FY26 following a strategic reset focused on its US operations, cutting costs by over 30% and repositioning for growth in FY27 with a stronger digital pipeline.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Botanix Pharmaceuticals clarifies its lead product Sofdra is unlikely to face price cuts under the proposed US executive order on drug pricing, citing its exclusive US market approval and distinct formulations abroad.